- Home
- DNUT vs CVAC Comparison
DNUT vs CVAC Comparison
Compare DNUT & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNUT
- CVAC
- Stock Information
- Founded
- DNUT 1937
- CVAC 2000
- Country
- DNUT United States
- CVAC Germany
- Employees
- DNUT N/A
- CVAC N/A
- Industry
- DNUT Food Chains
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- DNUT Consumer Staples
- CVAC Health Care
- Exchange
- DNUT Nasdaq
- CVAC Nasdaq
- Market Cap
- DNUT 917.1M
- CVAC 818.8M
- IPO Year
- DNUT 2021
- CVAC 2020
- Fundamental
- Price
- DNUT $4.92
- CVAC $2.77
- Analyst Decision
- DNUT Buy
- CVAC Hold
- Analyst Count
- DNUT 8
- CVAC 3
- Target Price
- DNUT $13.13
- CVAC $10.00
- AVG Volume (30 Days)
- DNUT 3.1M
- CVAC 620.8K
- Earning Date
- DNUT 05-08-2025
- CVAC 05-22-2025
- Dividend Yield
- DNUT 2.85%
- CVAC N/A
- EPS Growth
- DNUT N/A
- CVAC N/A
- EPS
- DNUT 0.02
- CVAC N/A
- Revenue
- DNUT $1,665,397,000.00
- CVAC $70,565,734.00
- Revenue This Year
- DNUT $1.24
- CVAC $742.57
- Revenue Next Year
- DNUT $12.40
- CVAC N/A
- P/E Ratio
- DNUT $274.40
- CVAC N/A
- Revenue Growth
- DNUT N/A
- CVAC 75.11
- 52 Week Low
- DNUT $4.87
- CVAC $2.22
- 52 Week High
- DNUT $16.05
- CVAC $5.28
- Technical
- Relative Strength Index (RSI)
- DNUT 27.20
- CVAC 38.24
- Support Level
- DNUT $5.38
- CVAC $2.78
- Resistance Level
- DNUT $5.59
- CVAC $3.33
- Average True Range (ATR)
- DNUT 0.25
- CVAC 0.15
- MACD
- DNUT 0.06
- CVAC -0.00
- Stochastic Oscillator
- DNUT 5.75
- CVAC 8.20
About DNUT Krispy Kreme Inc.
Krispy Kreme Inc is a sweet treat brand company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in-your-mouth experience. It operates through its network of fresh Doughnut Shops, partnerships with retailers, and a growing e-commerce and delivery business. The company conducts its business through the following three reported segments: U.S., which includes all operations in the United States; International, which includes operations in the U.K., Ireland, Australia, New Zealand, Canada, Japan, and Mexico; and Market Development, which includes franchise operations across the globe. It derives maximum revenue from the U.S. segment.
About CVAC CureVac N.V.
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.